anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis represents a profound challenge in critical care, characterized by a severe systemic inflammatory response which can lead to multi-organ failure and death. The intricate pathophysiology of sepsis involves an overwhelming immune reaction that disrupts normal host defense mechanisms, necessitating innovative approaches to modulation. Nanoscale immunomodulators, with their precision targeting and controlled release capabilities, have emerged as a potent solution to recalibrate immune responses in sepsis. This review explores the recent advancements in nanotechnology for sepsis management, emphasizing the integration of nanoparticulate systems to modulate immune function and inflammatory pathways. Discussions detail the development of the immune system, the distinct inflammatory responses triggered by sepsis, and the scientific principles underpinning nanoscale immunomodulation, including specific targeting mechanisms and delivery systems. The review highlights nanoformulation designs aimed at enhancing bioavailability, stability, and therapeutic efficacy, which shows promise in clinical settings by modulating key inflammatory pathways. Ultimately, this review synthesizes the current state of knowledge and projects future directions for research, underscoring the transformative potential of nanolevel immunomodulators for sepsis treatment through innovative technologies and therapeutic strategies.
A pharmaceutical composition for treating diseases related to inflammation or injury such as ARDS, comprising: (a) an active material derived from human somatic cells, the active ingredient being an extracellular vesicle produced by human somatic cells; and (b) a pharmaceutically acceptable carrier. The somatic cells are selected from human tissue, bone marrow and/or blood-derived stem cells, etc. The dosage form of the pharmaceutical composition is selected from an atomized inhalation agent, eye drops and nasal drops. The pharmaceutical composition has storage stability and high dispersibility superior to those of a living cell formulation. A method for preparing an extracellular vesicle, comprising steps of culturing human somatic cells, removing cells from a culture system, mixing a culture solution with polyethylene glycol to form an extracellular vesicle modified by PEG, centrifuging, resuspending, etc. The formulation of the extracellular vesicle can be used for preparing a medicament for preventing and/or treating inflammations or injuries.
Determination of body composition (the relative distribution of fat, muscle, and bone) has been used effectively to assess the risk of progression and overall clinical outcomes in different malignancies. Sarcopenia (loss of muscle mass) is especially associated with poor clinical outcomes in cancer. However, estimation of muscle mass through CT scan has been a cumbersome, manually intensive process requiring accurate contouring through dedicated personnel hours. Recently, fully automated technologies that can determine body composition in minutes have been developed and shown to be highly accurate in determining muscle, bone, and fat mass. We employed a fully automated technology, and analyzed images from a publicly available cancer imaging archive dataset (TCIA) and a tertiary academic center. The results show that adrenocortical carcinomas (ACC) have relatively sarcopenia compared to benign adrenal lesions. In addition, functional ACCs have accelerated sarcopenia compared to non-functional ACCs. Further longitudinal research might shed further light on the relationship between body component distribution and ACC prognosis, which will help us incorporate more nutritional strategies in cancer therapy.
Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
The oxalic acid-bis-hydroxy arylamide of the formula <FORM:0987798/C2/1> is prepared by the reaction of 1-amino-2- hydroxy-5-tertiarybutyl benzene with oxalic acid dichloride.ALSO:Polyacrylonitrile, polyvinyl chloride, polyvinyl acetate, poly-a -olefins, polyamides, polyesters, epoxy resins, polystyrene, alkyd resins, resins produced by the reaction of formaldehyde with phenol, urea or melamine, rubber, balata, guttapercha, polychloroprene, olefinic polysulphides and polybutadiene are protected against ultra-violet light by incorporating therein an oxalic acid-bis-hydroxyarylamide having the formula <FORM:0987798/C3/1> in which A is a benzene residue. Compounds having the formula <FORM:0987798/C3/2> in which X is a hydrogen or chlorine atom, an alkyl radical with 1-12 carbon atoms, a methoxy group or a phenyl or cyclohexyl group are preferably used. The compound may be incorporated into synthetic polymers before, during or after polymerization.  The treated materials may be used for the production of fibres or films, for treating textiles or as lacquers. 0.01-10% by weight of the compound may be incorporated.ALSO:Halic acid-bis-hydroxyarylamides having the formula <FORM:0987798/C4-C5/1> in which A is a benzene residue are incorporated into oils, fats, waxes, candles, polishes and soaps to protect them against ultraviolet light. Compounds having the formula <FORM:0987798/C4-C5/2> in which X is a hydrogen or chlorine atom, an alkyl radical with 1-12 carbon atoms, a methoxy group or a phenyl or cyclohexyl group are preferably used.  0.01-10% by weight of the compounds may be incorporated.ALSO:Oxalic acid-bis hydroxy aryamides having the formula <FORM:0987798/A5-A6/1> in which A is a benzene residue are incorporated into perfumes, bath salts, skin and face creams, powders, insect repellants and sunburn oils and creams to protect them against ultraviolet light. Compounds having the formula <FORM:0987798/A5-A6/2> in which X is a hydrogen or chlorine atom, an alkyl radical with 1-12 carbon atoms, a methoxy group or a phenyl or cyclohexyl group are preferably used.  0,01-10% by weight of the compounds may be used.ALSO:Textile materials, e.g. wool, silk, cotton, hemp, flax, linen, jute, ramie, regenerated cellulose, acetate rayon, cellulose triacetated polyacrylonitrile, polyvinyl chloride, poly-a -olefin, polyamide or polyester fibres, feathers, straw, wood, wood pulp, paper, cardboard or chip board are protected against ultra-violet light by applying thereto an oxalic acid-bis hydroxyacrylamide having the formula <FORM:0987798/D1-D2/1> in which A is a benzene residue.  Compounds having the formula <FORM:0987798/D1-D2/2> in which X is a hydrogen or chlorine atom, an alkyl radical with 1-12 carbon atoms, a methoxy group or a phenyl or cyclohexyl group are preferably used.  The compound may be applied together with starch, casein, polyvinyl acetate or polymeric derivatives of acrylic acid.  0. 01-10% by weight of the compound may be applied.
The invention relates to a traditional Chinese medicinal composition for treating chronic leukemia. The traditional Chinese medicinal composition is prepared from the following medicinal materials in parts by weight: 200-500 parts of placenta hominis, 300-500 parts of tortoise plastron, 60-110 parts of cornua cervi pantotrichum, and 50-100 parts of dried rehmannia roots. A preparation method of the traditional Chinese medicinal composition comprises the following steps: washing the medicinal materials to be clean, drying the washed medicinal materials, smashing the dried medicinal materials till the granularity is 80-mesh, carrying out disinfection and sterilization, and packaging micelles. For the traditional Chinese medicinal composition, totally, eight chronic leukemia patients, including five male patients and three female patients are admitted and treated clinically, the youngest is 19 years old, the oldest is 46 years old, and chemotherapy is carried out for twice at least, and three years at most. After the patients take the medicine provided by the invention, the patients recovering rapidly are radically treated after half a year, and in order to prevent the relapse, the patients need to take the medicine for one year persistently. The traditional Chinese medicinal composition is simple in formula, wide in raw material source, low in treatment cost, rapid in taking effect, and free of side effects.
In the last few decades, the world has seen a significant increase in the occurrence of occupational diseases related to Burnout Syndrome (professional exhaustion) and stress in educators. These disorders affect mental health and teaching activity. In this way, they need to develop socio-emotional skills to cope with the psychosocial stressors related to the school environment. Currently, mindfulness-based therapies have been recommended to help educators acquire emotional self-control, and to improve self-esteem, metacognition, attention, resilience and affectivity, in addition to better the social skills needed in the school milieu. A few published studies indicate that mindfulness practices also reduce some inflammation- and stress- related molecules such as cortisol, receptor-interacting serine/threonine kinase 2 (RIPK2), cyclooxygenase 2 (COX2), interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and epigenetic-regulation related histone deacetilases (HDAC). These indicator molecules can be measured in blood. The World Health Organisation (WHO-2013) recommends the worldwide implementation of strategies for the promotion of mental health, which are particularly aimed at preventing occupational diseases. The main objective of the proposed research project is to elaborate a program of Mindfulness-Based Health Promotion - educators (MBHP - educa) to be applied to a population of Brazilian public school educators. The efficacy of the program will be evaluated by cognitive testing. Blood tests for the above-mentioned stress-related molecules will be performed. The goal of developing the MBHP - educa Program is to promote and ameliorate the health care of public school teachers. Developing such a research proposal will contribute to debate and implement public health policies focussed on promoting the health of public school teachers in Brazil.
PROBLEM TO BE SOLVED: To provide a means for improving the gustatory flavor of extract from the flower part of basswood (e.g. Tilia cordata Mill. or Tilia platyphyllos Scop.) which is hard to be utilized because of having unpleasant gustatory flavor so as to make the flower part of basswood easily takable in the form of food and drink. SOLUTION: This means comprises the steps of mixing at least one kind of compound selected from the group consisting of sugar alcohols (e.g. erythritol, xylitol), citric acid, malic acid, lactic acid, phosphoric acid and monosaccharides wherein its sweetness is 0.1 to 0.7 time that of sucrose (e.g. glucose, xylose) and disaccharides (e.g. maltose, lactose) with an extract from the flower part of basswood.
This study aims to investigate how electroacupuncture regulates the learning and memory abilities of poststroke cognitive impairment (PSCI) rats through the TLR4/NF-κB/NLRP3 signaling pathway on the hippocampal microglia. Thirty male rats were randomly divided into three groups: sham surgery group, PSCI model group, and electroacupuncture group, with 10 rats in each group. Middle cerebral artery occlusion was used to establish the PSCI model. The Zea Longa method was used to score the rats' neurological function. Electroacupuncture was utilized for 21 days to improve PSCI. The learning and memory abilities of rats were tested using the Morris water maze. Hematoxylin-eosin staining and immunofluorescence were used to find the hippocampus' pathological changes. The concentration of interleukin-1β, interleukin-6, tumor necrosis factor-α, and interleukin-18 were detected by ELISA. The mRNA expression levels of associated inflammatory corpuscles were measured by quantitative real-time PCR. The protein expression levels of TLR4, MyD88, NF-κB, and NLRP3 were measured using western blotting. Electroacupuncture improved not only the learning and memory abilities of PSCI rats but also hippocampal morphology. Electroacupuncture inhibited the activation of microglia and the TLR4/NF-κB/NLRP3 signaling pathway. Electroacupuncture also reduced proinflammatory factors and restrained the mRNA levels of NLRP3-associated inflammatory cytokines. Its mechanism was related to inhibiting the expression of the TLR4/NF-κB/NLRP3 signaling pathway, attenuating the release of inflammatory factors, and regulating the activation of hippocampal microglia in the brain.
Topoisomerase II alpha (topo IIα) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo IIα is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo IIα to the export receptor CRM1. Inhibition was specific to topo IIα as p53 trafficking was unaffected along with topo IIα protein expression and function (decatenation). These topo IIα-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor.
Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status [see Overdosage (10)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. 

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of ASCOMP with CODEINE, the risk is greatest during the initiation of therapy or following a dosage increase. 

Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with and following dosage increases of ASCOMP with CODEINE. 

To reduce the risk of respiratory depression, proper dosing and titration of ASCOMP with CODEINE are essential [see Dosage and Administration (2.1)]. Overestimating the ASCOMP with CODEINE dosage when converting patients from another opioid product can result in a fatal overdose with the first dose. 

Accidental ingestion of ASCOMP with CODEINE, especially by children, can result in respiratory depression and death due to an overdose of codeine and butalbital.

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see Dosage and Administration (2.3)].
Risperidone tablets can be administered once or twice daily. Initial dosing is 2 mg/day. May increase the dose at intervals of 24 hours or greater, in increments of 1 to 2 mg/day, as tolerated, to a recommended dose of 4 to 8 mg/day. In some patients, slower titration may be appropriate. Efficacy has been demonstrated in a range of 4 to 16 mg/day. However, doses above 6 mg/day for twice daily dosing were not demonstrated to be more efficacious than lower doses, were associated with more extrapyramidal symptoms and other adverse effects, and are generally not recommended. In a single study supporting once daily dosing, the efficacy results were generally stronger for 8 mg than for 4 mg. The safety of doses above 16 mg/day has not been evaluated in clinical trials [see Clinical Studies (14.1)].
Flumazenil was studied in four trials in 644 patients who received midazolam as an induction and/or maintenance agent in both balanced and inhalational anesthesia. Midazolam was generally administered in doses ranging from 5 mg to 80 mg, alone and/or in conjunction with muscle relaxants, nitrous oxide, regional or local anesthetics, narcotics and/or inhalational anesthetics. Flumazenil was given as an initial dose of 0.2 mg IV, with additional 0.2 mg doses as needed to reach a complete response, up to a maximum total dose of 1 mg. These doses were effective in reversing sedation and restoring psychomotor function, but did not completely restore memory as tested by picture recall. Flumazenil was not as effective in the reversal of sedation in patients who had received multiple anesthetic agents in addition to benzodiazepines.

Eighty-one percent of patients sedated with midazolam responded to flumazenil by becoming completely alert or just slightly drowsy. Of those patients, 36% responded to doses of 0.4 mg to 0.6 mg, while 64% responded to doses of 0.8 mg to 1 mg.

Resedation in patients who responded to flumazenil occurred in 10% to 15% of patients studied and was more common with larger doses of midazolam (>20 mg), long procedures (>60 minutes) and use of neuromuscular blocking agents. (See PRECAUTIONS.)
The invention provides a fat emulsion injection and a preparation method thereof. The fat emulsion injection solves the problems of the prior art. The preparation method improves fat emulsion stability, has simple processes and is convenient for operation. Through the preparation method, few fat peroxides are produced or few aldehydes and ketones are produced by continuous decomposition of the fat peroxides. The fat emulsion injection and the preparation method thereof are shown in the patent specification. The fat emulsion injection contains components shown in the patent specification.
PURPOSE: This paper aims to describe the study design and baseline characteristics of the Sri Lanka Child Growth Cohort (SLCGC), which was established to assess the timing, pattern and determinants of growth faltering in infants and young children in Sri Lanka.
PARTICIPANTS: A retrospective cohort study was conducted among term-born babies (≥37-week gestation), currently aged between 12 and 24 months. A sample of 1875 mother-child pairs were recruited using two-stage stratified cluster sampling method. Data on sociodemographic characteristics, pregnancy care, feeding practices, childhood illnesses and home risk factors were collected through direct interviews with the caregivers. Pregnancy-related data were obtained from the pregnancy record. Birth weight, serial weight and length records and growth pattern were extracted from the Child Health and Development Record. Current weight and length of the children were measured directly.
FINDINGS TO DATE: The SLCGC serves as a comprehensive cohort study with a countrywide distribution in Sri Lanka, covering the three main residential sectors, namely the urban, rural and estate sectors in equal proportions. The majority of mothers were housewives (76.8%) and aged <35 years (77.9%). The proportions achieved secondary education in mothers and fathers were 69.0% and 63.7%, respectively. Approximately 30% of mothers were overweight or obese, while 15% were underweight on entry to antenatal care. Of the children, 49.2% were girls, 42.5% were the first-born children in their family and 34.2% were born by caesarean section. Mean birth weight was 2917 g (SD 0.406), with the proportion of low birth weight (less than 2500 g) being 13%.
FUTURE PLANS: This data enables investigation of the effects of single exposures on child growth, as well as, more complex epidemiological analyses on multiple simultaneous and time-varying exposures. Data will be available for researchers for further analysis. The next wave of assessment is expected to be done after 12 months.
Bangladesh is one of the countries having highest proportions of malnourished children in the world. The Bangladesh Integrated nutrition Project (BINP) is a recent initiative of the Government of Bangladesh to reduce malnutrition of women and children under two years of age. The BINP includes a specific programme to address severely malnourished children at the community level, however there is no such programme directed toward moderately malnourished children. Moderately malnourished children form a large proportion of children in the community, and with success of the BINP, this proportion is growing, as severely malnourished children shift to the moderately malnourished category. To address this, operations research will be undertaken in a BINP thana named Shahrasti, in Chandpur District over a 6 month period. A total of 300 children in three groups from Community Nutrition Centres (CNC) will be studied. There will be groups in the study. In addition to usual component of the BINP, mothers of the first group of intervention will receive intensive nutrition education and motivation for child care, complementary food demonstration, and household food mobilization for child feeding weekly for first four weeks then reinforced every two weeks. The second intervention group will receive a packet of the usual BINP food supplement daily for 6 days a week for 3 months and nutrition education at the same intensity. The third group will be a control group and will receive only the usual programme inputs of BINP and their weight gain will be recorded. The CNP, women group and village nutrition committee will be involved. Focus group discussion will be held with mothers. Data on morbidity will be collected and necessary medical advise will be given equal to each group. Data collection, counseling on child caring practice, food demonstration and nutrition education using IEC will be organized and supervised by project staff. It is assumed that if the intervention is successful, and once the nutritional status improves, they are likely to maintain good health. The IEC on dietary practice will be communicated to the village members for preventive measures. Data will be analyzed for change in nutrition groups from moderate to mild malnutrition or normal nutrition and will be compared between the control and two intervention groups. It is expected that the results of the study will help to address to reduce moderate malnutrition existing in the large proportion of malnourished children. This will in turn reduce the risk of regressing to severe malnutrition.